CompletedNot Applicable

Written Exposure Therapy to Improve Recovery Among Sexual Assault Survivors

United States30 participantsStarted 2024-09-23

Plain-language summary

The main objective of this pilot trial is to determine the feasibility and initial efficacy of telehealth-delivered written exposure therapy to reduce the development of posttraumatic stress disorder after sexual assault. This pilot trial will provide the data necessary to design and support a large-scale trial.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Cisgender woman * Writes and speaks English * 18+ years of age * Presents for SANE care within 7 days of sexual assault * Discharged home after SANE care * Has an email address * Has an Apple (iOS) or Android-compatible smartphone with photo capability (for writing session upload), without loss of cellular connection due to inability to pay bill for \>1 year * Willing to participate in remote therapy sessions * Meets PTSD risk score criteria * Meets with research assistant (RA) for informed consent within 30 days of SANE care Exclusion Criteria: * Age \<18 * Pregnant * Incarcerated or in police custody * Presented for SANE care \>7 days after assault * Has had a change in psychiatric medication regimen 1 month prior to study enrollment * Currently receiving cognitive-behavioral therapy or exposure-based psychological treatment * Sexually assaulted at work or by a colleague * Currently lives with the person who assaulted them * History or condition that in investigator's judgment would likely make a participant non-compliant/unsuitable for participation, including deafness or blindness

What they're measuring

Changes in PTSD Symptom Severity Over Time

Timeframe: Baseline, Week 4, Week 8, Month 3, Month 5

Recruitment Rates

Timeframe: Baseline

Retention Rates

Timeframe: Month 5

Treatment Completion Rates

Timeframe: Week 8

Trial details

NCT IDNCT06571513

SponsorUniversity of North Carolina, Chapel Hill

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-03-07